-- Alan Mozes
WEDNESDAY, Nov. 30 (HealthDay News) -- In the vast majority of
cases, researchers can distinguish between Alzheimer's and another
form of dementia with shared symptoms by using a specific type of
PET scan that looks for evidence of plaque in the brain, new
Known as the "PIB PET" scan, this type of scan appears to be
more accurate in telling apart the two types of dementia than the
more commonly used "FDG PET" scan.
"These two types of dementia share similar symptoms, so telling the two apart while a person is living is a real challenge, but important so doctors can determine the best form of treatment," study author Dr. Gil Rabinovici of the University of California San Francisco Memory and Aging Center explained in a university news release.
The study is in the Nov. 30 online issue of
The PIB PET scan harnesses a "PIB marker" to uncover signs of
brain plaque (known as amyloid). The presence of such plaque is a
telltale sign of Alzheimer's, but is not a signal of another type
of dementia called frontotemporal lobar degeneration (FTLD).
In FTLD, the frontal and temporal lobes of the brain atrophy.
It's less common than Alzheimer's, but equally as devastating.
People with FTLD can develop erratic behavior, emotional problems,
trouble communicating and difficulty with walking and other basic
To gauge the effectiveness of PIB PET scans, the team focused on
107 patients who either had early onset Alzheimer's or FTLD.
All the patients underwent both the PIB PET scan and the FDG PET
scan. The latter looks for signs of metabolic changes in the
While the FDG PET scan was found to accurately differentiate
between the two forms of dementia nearly 78 percent of the time,
PIB PET scans did so nearly 90 percent of the time.
Although the study found that FDG PET resulted in fewer false
positives in select situations, overall, PIB PET appeared to
"While widespread use of PIB PET scans isn't available at this time, similar amyloid markers are being developed for clinical use, and these findings support a role for amyloid imaging in correctly diagnosing Alzheimer's disease vs. FTLD," Rabinovici noted.
Catherine Roe, an assistant professor of neurology with the
Knight Alzheimer's Disease Research Center at Washington University
School of Medicine in St. Louis, said that currently PIB PET
technology is impractical to deploy outside of specialized research
institutions. But that, she noted, is about to change.
"The authors are correct in saying that new amyloid marking technology is being developed right now that will be easier to use in a clinical setting," she said. "Testing is underway. So based on their findings their support for the use of this type of scan makes really good sense to me. Because 90 percent sensitivity in correctly identifying disease is a lot better than 78."
For more on Alzheimer's, visit the
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.